In 2025, the U.S. Food and Drug Administration (FDA) approved 46 new drugs, a modest decrease from recent years but reflecting important changes in how pharmaceutical companies are designing treatments. Of these approvals, 34 were new chemical entities (including peptides and oligonucleotides), while 12 were biologics—a category that includes monoclonal antibodies, antibody-drug conjugates, and proteins. The shift in these numbers tells an important story about where drug development is heading and what treatments patients might expect in the coming years. Why Did FDA Drug Approvals Decline in 2025? The 46 approvals in 2025 represent a decrease compared to the average of approximately 50 drugs approved annually between 2018 and 2024. However, this decline doesn't necessarily reflect weakness in the pharmaceutical industry itself. Instead, experts point to systemic issues related to the new U.S. administration, which has placed increased scrutiny on the pharmaceutical sector. Despite this slowdown, the approval rate remains historically strong compared to earlier decades—the FDA approved an average of just 25 drugs per year during 2000 to 2010. What Types of Drugs Are Dominating the Market? Monoclonal antibodies (mAbs)—proteins designed to target specific disease-causing molecules—continue to dominate the biologics landscape. More than 90% of all approved biologics contain or are mAb components, and they now represent nearly 25% of all FDA-approved drugs overall. Cancer remains the primary focus for these therapies, though mAb-based treatments are increasingly being applied to other disease areas like autoimmune conditions and infectious diseases. Among the 12 biologics approved in 2025, nine were monoclonal antibodies, two were antibody-drug conjugates (ADCs)—a newer class combining antibodies with cancer-fighting chemicals—and one was a fusion protein. The approval of two ADCs in 2025 is particularly noteworthy because no ADCs had been approved in the previous two years. This brings the total number of FDA-approved ADCs to 16 to date. Which Disease Areas Saw the Most New Treatments? Cancer treatment dominated the 2025 approvals. Several of the newly approved drugs target specific types of cancer, including breast cancer, lung cancer, nasopharyngeal carcinoma, and multiple myeloma. Beyond oncology, the FDA also approved treatments for hereditary angioedema (a rare swelling disorder), myasthenia gravis (an autoimmune muscle weakness condition), asthma, and immunoglobulin A nephropathy (a kidney disease). Vaccines also played an important role in 2025 approvals. The Center for Biologics Evaluation and Research approved nine biologics licenses in 2025, including two COVID-19 vaccines from ModernaTX and Novavax, as well as new vaccines for chikungunya and meningococcal disease. This underscores the continued importance of vaccine development for public health, despite some societal opposition to vaccination programs. How Are Drug Molecules Changing? From a chemical perspective, the drugs approved in 2025 reveal important trends in molecular design. Small molecules—the traditional pill-based drugs—continue to dominate, with a high prevalence of specific chemical features. Most newly approved small molecules contain N-aromatic moieties (nitrogen-containing ring structures) and fluorine atoms, which help drugs bind more effectively to their targets and improve how the body processes them. A growing category called TIDES (Targeted Immunomodulatory Degraders and Extracellular Signaling molecules)—which includes oligonucleotides and peptides—continues to expand its market presence. In 2025, four TIDES drugs were approved, representing nearly 10% of total approvals. Of these, three were oligonucleotides designed with a special liver-targeting technology using N-acetylgalactosamine (GalNAc), which helps deliver these drugs specifically to liver cells. Steps to Understanding the New Drug Landscape - Monoclonal Antibodies (mAbs): These engineered proteins now represent over 90% of all approved biologics and are increasingly used beyond cancer to treat autoimmune diseases, infectious diseases, and inflammatory conditions. - Antibody-Drug Conjugates (ADCs): This emerging class combines antibodies with potent cancer-fighting chemicals, allowing drugs to target tumors more precisely while reducing damage to healthy cells. - Oligonucleotide Therapies: These genetic-based drugs use specialized delivery systems like GalNAc to reach specific organs, offering new treatment options for previously hard-to-treat diseases. - Small Molecule Design: Modern drugs increasingly incorporate fluorine atoms and aromatic structures to improve how effectively they bind to disease targets and how the body processes them. What Challenges Remain for the Pharmaceutical Industry? Despite these advances, significant challenges persist. Manufacturing peptides and oligonucleotides remains complex and expensive, and sustainability concerns have emerged around the use of PFAS (per- and polyfluoroalkyl substances)—chemicals used in drug manufacturing that can accumulate in the environment and human tissue. Additionally, the high cost of innovative therapies limits access, particularly in low- and middle-income countries where patients have the greatest need for affordable treatments. The 2025 approval data reveals a pharmaceutical industry in transition. While the total number of approvals declined slightly, the types of drugs being approved—particularly the growth of biologics and targeted therapies—suggest that future treatments will be more precise, more specialized, and increasingly focused on previously untreatable diseases. As these technologies mature and manufacturing becomes more efficient, the hope is that costs will decrease and access will improve globally.
